Semaglutide denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Semaglutide as "Not FDA-Approved" — and Why You Can Fight It

This denial almost always reflects a mismatch between the specific semaglutide product or formulation prescribed and the indication Aetna has on file for your case. Semaglutide is FDA-approved under multiple brand names for distinct indications. Aetna may apply this denial code when the prescribed formulation is being used for an indication outside the exact wording of its approval, or when compounded semaglutide is involved. It is worth noting that only FDA-approved branded products are generally coverable; compounded versions occupy a separate and more limited regulatory space.

## Your Federal Appeal Rights

You have layered federal protections regardless of whether your plan is fully insured or self-funded:

• ACA §2719 / ERISA §503 internal appeal: You must first exhaust your plan's internal appeal process. Submit a written appeal within the timeframe shown on your Explanation of Benefits (EOB), typically 180 days from the denial date.
• External review: After an adverse internal determination, ACA §2719 entitles most plan members to an independent external review by an accredited Independent Review Organization (IRO). The external-review window is generally within four months of the final internal denial.
• Expedited review: If a standard timeline would seriously jeopardize your health, you may request expedited internal and external review simultaneously, with decisions typically required within 72 hours.

## What to Gather Before You Appeal

1. The denial letter and Aetna's published coverage policy for semaglutide — download the exact policy from Aetna's website or request it in writing. Every criterion in that policy becomes a checklist item. 2. The FDA-approved prescribing information (label) for the specific semaglutide product prescribed — confirm your prescriber is using it within an approved indication. 3. Diagnosis documentation: ICD codes and clinical notes establishing the covered diagnosis (e.g., type 2 diabetes, obesity/chronic weight management). 4. Prescriber's medical-necessity letter: Your physician should explain, in the language of Aetna's own policy criteria, exactly why this product and indication apply to you. 5. Prior-treatment history: Dates and outcomes of any earlier therapies, showing why alternatives were inadequate.

## Criteria-Mapping Structure

Build a table: in the left column, paste each requirement verbatim from Aetna's coverage policy and the FDA label's approved indication. In the right column, cite the exact chart entry, lab date, or clinical note that satisfies it. Reviewers are looking for a one-to-one match — gaps in your mapping are the gaps they will deny on.

## Key Argument

If your prescriber is using an FDA-approved product within its approved labeling, the "not FDA-approved" code is factually incorrect and should be overturned on that basis alone. Include a copy of the FDA approval summary and the product label as exhibits.